Perceptic

Active

Overview

Perceptic is a London-based B2B software company developing an AI operating system for drug development. Its platform connects scientific evidence, proprietary and external data, decisions, and workflows across pharmaceutical research and clinical development. The company is positioned as an orchestration and intelligence layer above existing systems rather than as a standalone drug-discovery model provider.

History

Perceptic Technologies Limited was incorporated in England and Wales under company number 16054598, with its registered office in London. Public company profiles identify the business as founded in 2024. It was founded by Tilman Flock and two other former Palantir executives who worked in Palantir’s Life Sciences practice. Perceptic emerged from stealth in May 2026 with a reported $12 million seed round and deployments at CSL and multiple large pharmaceutical companies.

Product Lines

Product Line	Positioning	Price Range
Scout — asset intelligence	External asset scouting and portfolio triage for biopharma teams	Custom enterprise pricing
PercepticOS — scientific intelligence layer	Hypothesis testing, evidence synthesis, and institutional knowledge management	Custom enterprise pricing
Atlas — clinical data foundation	Unified internal and external clinical-trial data infrastructure	Custom enterprise pricing

Manufacturing

Perceptic provides enterprise software rather than physical products. Its platform is infrastructure- and model-agnostic, designed to connect customers’ existing data, tools, hardware, and AI models; no separate in-house manufacturing operation is indicated.

Notable Products

Scout - AI application for triaging external drug-development assets, licensing candidates, competitive programs, and pipelines against a customer’s strategy.
PercepticOS - Shared intelligence layer for testing scientific hypotheses, comparing internal evidence with external benchmarks, and retaining organizational knowledge.
Atlas - Clinical data foundation that brings together internal and external trial data for analysis and downstream workflows.

Reputation

Perceptic is presented by company and investor materials as enterprise infrastructure for pharmaceutical R&D, with reported deployments at CSL and other large pharmaceutical organizations. Public descriptions cite faster asset evaluation and a substantial increase in clinical-data extraction in customer deployments. Because the company is young and enterprise-focused, independent long-term reviews and broad enthusiast commentary remain limited. Its principal differentiation is the attempt to connect multiple AI applications and existing data systems, while its early-stage status means product performance and market durability have limited public validation.

Sources (10)